BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Shree Ganesh Remedies Ltd. Share Price

NSE
BSE

BSE : 540737

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

High

Price Summary

Previous Close ₹645.80
Day's Range ₹635.00 - ₹649.00
Open ₹635.00
52 Week Range ₹381.10 - ₹759.00
Volume 1,806
Market Cap ₹0.00

Stocks Summary

Trade Value ( ₹ in Lacs) 11.63
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.00
Price/Earning (TTM) 46.68
TTM EPS (₹) 13.83
P/E Ratio 39.58
Book Value(₹) 5.09
PAT Margin (%) 20.71
Face Value (₹) 10.00
ROCE(%) 19.53

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 244.32 1085.96
Expenses N/A N/A
PBT 87.81 312.68
Operating profit 0.0 0.0
Net profit 65.97 230.68

Shareholding Pattern

Promoters (% Holding)

72.84%

Mutual funds (% Holding)

0.00%

Non-Institution (% Holding)

26.64%

FI/Banks/Insurance (% Holding)

0.00%

Government (% Holding)

0.00%

FII

0.00%

About Shree Ganesh Remedies Ltd.

Founded 1995
Managing Director Chandulal Manubhai Kothia

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,67,870.32 2,015.50 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 2,20,945.52 8,600.00 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,90,906.63 5,160.00 3,480.60 - 3,480.60
Apollo Hospitals Enterprise Ltd. 1,26,818.07 8,900.00 6,696.50 - 6,696.50
Cipla Ltd. 1,18,673.63 1,500.00 1,165.70 - 1,165.70
Zydus Lifesciences Ltd. 1,11,346.37 1,126.00 835.50 - 835.50
Lupin Ltd. 1,08,639.01 2,569.10 1,836.80 - 1,836.80
Max Healthcare Institute Ltd. 1,06,086.80 1,093.00 903.00 - 903.00
Mankind Pharma Ltd. 1,02,193.79 2,535.00 1,909.70 - 1,909.70
Lenskart Solutions Ltd. 98,733.25 575.00 0.00 - 0.00
no-content No Records Found

Latest News

May
14
2026
EQUITY Posted on May 14th 2026

Shree Ganesh Remedies informs about outcome of board meeting

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Shree Ganesh Remedies has informed that the Board of Directors of the Company at its meeting held on today, Thursday, May 14, 2026 have considered and approved following: 1. Audited Financial Results (Standalone and Consolidated) of the company for the quarter and the financial year ended on March 31, 2026, along with the reports of Auditors thereon pursuant to Regulation 33 of SEBI LODR Regulations. Copy of the said Financial Results (Standalone and Consolidated) and Auditors Report is enclosed. Pursuant to Regulation 33 of SEBI LODR Regulations, it has declared that the statutory auditors have issued (Standalone and Consolidated) Audit Reports with unmodified opinion on the financial results of the Company for the year ended March 31, 2026; 2. Re-appointment of S N D K & Associates LLP, Chartered Accountants (Firm Registration No: W100060) as an Internal Auditors of the Company for the FY 2026-27. Details as required under Regulation 30 of the SEBI Listing Regulations read along with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762 /2026 dated January 30, 2026 are given as Annexure ‘A’. The Board of Directors Meeting commenced at 03:30 pm and concluded at 04:10 pm.

The above information is a part of company’s filings submitted to BSE.
Read More
Aug
4
2026
COMPANY Posted on Aug 4th 2026

Glaxosmithkline Phar - Quaterly Results

The company witnessed a 14.86% growth in the revenue at Rs. 9244.20 millions for the quarter ended June 2026 as compared to Rs. 8048.30 millions during the year-ago period.Profit saw a slight increase of 23.76%to Rs. 2533.30  millions from Rs. 2047.00 millions.Operating profit surged to 3547.90 millions from the corresponding previous quarter of 2945.10 millions.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 9244.20 8048.30 14.86 9244.20 8048.30 14.86 37902.00 37234.90 1.79
Other Income 616.30 437.60 40.84 616.30 437.60 40.84 1425.60 1425.60 0.00
PBIDT 3547.90 2945.10 20.47 3547.90 2945.10 20.47 14427.60 13118.50 9.98
Interest 9.70 4.20 130.95 9.70 4.20 130.95 27.30 13.10 108.40
PBDT 3538.20 2940.90 20.31 3538.20 2940.90 20.31 14426.70 13152.30 9.69
Depreciation 158.40 155.20 2.06 158.40 155.20 2.06 664.40 667.90 -0.52
PBT 3379.80 2785.70 21.33 3379.80 2785.70 21.33 13762.30 12484.40 10.24
TAX 846.50 738.70 14.59 846.50 738.70 14.59 3644.10 3293.80 10.64
Deferred Tax 33.00 0.20 16400.00 33.00 0.20 16400.00 94.60 62.00 52.58
PAT 2533.30 2047.00 23.76 2533.30 2047.00 23.76 10118.20 9190.60 10.09
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 38.38 36.59 4.88 38.38 36.59 4.88 38.07 35.23 8.04
Read More
Aug
4
2026
COMPANY Posted on Aug 4th 2026

Park Medi World - Quaterly Results

The Sales for the quarter ended June 2026 of Rs. 335.32 millions rose by 45.99% from Rs. 229.69 millions.A big loss of -77.86% reported for the quarter ended June 2026 to Rs. 10.84  millions from Rs. 48.97 millions.Operating profit for the quarter ended June 2026 decreased to 59.52 millions as compared to 105.52 millions of corresponding quarter ended June 2025.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 335.32 229.69 45.99 335.32 229.69 45.99 1289.65 915.82 40.82
Other Income 46.68 2.01 2222.39 46.68 2.01 2222.39 103.35 20.70 399.28
PBIDT 59.52 105.52 -43.59 59.52 105.52 -43.59 627.05 261.09 140.17
Interest 8.60 32.98 -73.92 8.60 32.98 -73.92 127.55 123.43 3.34
PBDT 50.92 72.54 -29.80 50.92 72.54 -29.80 499.50 137.66 262.85
Depreciation 33.81 11.61 191.21 33.81 11.61 191.21 45.09 48.62 -7.26
PBT 17.11 60.93 -71.92 17.11 60.93 -71.92 454.41 89.04 410.34
TAX 6.27 11.96 -47.58 6.27 11.96 -47.58 88.25 17.24 411.89
Deferred Tax 2.83 -0.13 -2276.92 2.83 -0.13 -2276.92 -24.50 -20.83 17.62
PAT 10.84 48.97 -77.86 10.84 48.97 -77.86 366.16 71.80 409.97
Equity 863.86 768.80 12.36 863.86 768.80 12.36 863.86 768.80 12.36
PBIDTM(%) 17.75 45.94 -61.36 17.75 45.94 -61.36 48.62 28.51 70.55
Read More
Aug
4
2026
COMPANY Posted on Aug 4th 2026

Dr Agarwals Eye Hosp - Quaterly Results

The June 2026 quarter revenue stood at Rs. 1429.70 millions, up 22.28% as compared to Rs. 1169.20 millions during the corresponding quarter last year.A good growth in profit of 35.46% reported to Rs. 233.80  millions over Rs. 172.60 millions of corresponding previous quarter.The company reported a good operating profit of 452.20 millions compared to 379.30 millions of corresponding previous quarter.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 1429.70 1169.20 22.28 1429.70 1169.20 22.28 4708.70 3971.50 18.56
Other Income 19.60 8.00 145.00 19.60 8.00 145.00 58.20 50.90 14.34
PBIDT 452.20 379.30 19.22 452.20 379.30 19.22 1511.30 1235.90 22.28
Interest 27.70 41.60 -33.41 27.70 41.60 -33.41 118.80 134.40 -11.61
PBDT 424.50 337.70 25.70 424.50 337.70 25.70 1392.50 1101.50 26.42
Depreciation 114.90 105.80 8.60 114.90 105.80 8.60 456.40 394.50 15.69
PBT 309.60 231.90 33.51 309.60 231.90 33.51 936.10 707.00 32.40
TAX 75.80 59.30 27.82 75.80 59.30 27.82 235.10 160.50 46.48
Deferred Tax -0.90 0.10 -1000.00 -0.90 0.10 -1000.00 0.40 2.40 -83.33
PAT 233.80 172.60 35.46 233.80 172.60 35.46 701.00 546.50 28.27
Equity 48.30 47.00 2.77 48.30 47.00 2.77 48.30 47.00 2.77
PBIDTM(%) 31.63 32.44 -2.50 31.63 32.44 -2.50 32.10 31.12 3.14
Read More
Aug
4
2026
COMPANY Posted on Aug 4th 2026

Unjha Formulations - Quaterly Results

The sales for the June 2026 quarter moved down to Rs. 33.07 millions as compared to Rs. 36.34 millions during the year-ago period.Net profit of the cmpany stood at Rs. 1.57 millions for the quarter ended June 2026 a decline of -59.64% from Rs. 3.89 millions  in the same quarter last year.Operating Profit reported a sharp decline to 1.95 millions from 4.20 millions in the corresponding previous quarter.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 33.07 36.34 -9.00 33.07 36.34 -9.00 157.49 139.77 12.68
Other Income 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBIDT 1.95 4.20 -53.57 1.95 4.20 -53.57 11.04 6.30 75.24
Interest 0.01 0.02 -50.00 0.01 0.02 -50.00 0.08 0.08 0.00
PBDT 1.94 4.18 -53.59 1.94 4.18 -53.59 10.96 6.22 76.21
Depreciation 0.37 0.29 27.59 0.37 0.29 27.59 1.42 0.98 44.90
PBT 1.57 3.89 -59.64 1.57 3.89 -59.64 9.54 5.24 82.06
TAX 0.00 0.00 0.00 0.00 0.00 0.00 2.49 1.16 114.66
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 -0.08 -0.01 700.00
PAT 1.57 3.89 -59.64 1.57 3.89 -59.64 7.05 4.08 72.79
Equity 44.81 44.81 0.00 44.81 44.81 0.00 44.81 44.81 0.00
PBIDTM(%) 5.90 11.56 -48.98 5.90 11.56 -48.98 7.01 4.51 55.52
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Shree Ganesh Remedies Ltd. ?

The current share price of Shree Ganesh Remedies Ltd. is ₹645.80 as of 2026-08-03.

The market capitalisation of Shree Ganesh Remedies Ltd. is ₹829.05 as of 2026-08-03.

The 1-year return of Shree Ganesh Remedies Ltd. is 69.95% as of 2026-08-03.

The P/E ratio of Shree Ganesh Remedies Ltd. is 39.58 as of 2026-08-04.

The 52-week high and low of Shree Ganesh Remedies Ltd. are ₹759.00 and ₹381.10, respectively, as of 2026-08-03.

The dividend yield of Shree Ganesh Remedies Ltd. is 0.0% as of2026-08-03.

You can buy Shree Ganesh Remedies Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Shree Ganesh Remedies Ltd. is Chandulal Manubhai Kothia.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore